Fatty Liver Disease MRI: Detection and Monitoring

Non-alcoholic fatty liver disease (NAFLD) — now increasingly called metabolic dysfunction-associated steatotic liver disease (MASLD) — is the most common liver condition in the UK, affecting an estimated 1 in 3 adults. Most people with fatty liver have no symptoms and do not know they have it. MRI is the most accurate non-invasive way to measure the amount of fat in your liver, detect inflammation, and assess whether scarring (fibrosis) has developed.

If blood tests have shown raised liver enzymes, if you have risk factors for fatty liver (overweight, type 2 diabetes, high cholesterol), or if ultrasound has suggested fatty changes, an MRI can tell you exactly how much fat is in your liver and whether any damage has occurred.

Understanding Fatty Liver Disease

Fatty liver disease is a spectrum:

• Simple steatosis (fatty liver) — fat accumulation in more than 5% of liver cells. Usually benign. Most people with simple fatty liver never develop serious liver problems.
• Steatohepatitis (NASH/MASH) — fatty liver with inflammation. Around 20-30% of people with simple fatty liver progress to this stage. This is the point where liver damage can occur.
• Fibrosis — scarring caused by ongoing inflammation. Graded from F0 (no fibrosis) to F4 (cirrhosis). Fibrosis stages F1-F2 are early and potentially reversible with lifestyle changes.
• Cirrhosis (F4) — severe scarring replacing normal liver tissue. Irreversible but manageable. Increases risk of liver failure and hepatocellular carcinoma (liver cancer).

Risk Factors

• Overweight/obesity — particularly central (abdominal) obesity
• Type 2 diabetes — up to 70% of type 2 diabetics have fatty liver
• High cholesterol and triglycerides
• Metabolic syndrome
• Polycystic ovary syndrome (PCOS)
• Hypothyroidism
• Age (risk increases with age)

How MRI Assesses Fatty Liver

MRI uses specialised techniques to measure liver fat and assess liver health:

• MRI-PDFF (Proton Density Fat Fraction) — the gold standard non-invasive measurement of liver fat. Measures the percentage of fat in the liver with high accuracy. Results correlate closely with liver biopsy. Normal is below 5%. Grading: mild steatosis 5-17%, moderate 17-22%, severe above 22%.
• MR elastography (MRE) — measures liver stiffness by sending mechanical vibrations through the liver and imaging them with MRI. Stiffness correlates with fibrosis stage. More accurate than ultrasound-based elastography (FibroScan) and is not affected by obesity, ascites, or operator skill. Available at specialised centres.
• Standard MRI sequences — T1/T2-weighted images show liver morphology, detect focal lesions, and identify signs of advanced liver disease (irregular contour, enlarged spleen, varices, ascites).
• In-phase and opposed-phase imaging — a screening technique where signal drop-out on opposed-phase images compared to in-phase images indicates fat in liver cells. Less precise than PDFF but available on all MRI scanners.

Comparison with Other Tests

• Ultrasound — can detect moderate-to-severe fatty liver but misses mild steatosis. Cannot reliably quantify fat or detect early fibrosis. Operator-dependent.
• FibroScan (transient elastography) — measures liver stiffness (as a proxy for fibrosis) using ultrasound-based elastography. Good screening tool but less accurate in obese patients and cannot quantify fat as precisely as MRI-PDFF. Also provides a controlled attenuation parameter (CAP) for fat estimation.
• Liver biopsy — the historical gold standard. Provides detailed tissue analysis (fat, inflammation, fibrosis) but is invasive, has sampling error, and carries a small risk of complications (bleeding, pain). Increasingly being replaced by MRI for fat quantification and monitoring.
• Blood tests (liver function tests) — ALT and AST can be raised in fatty liver with inflammation, but can also be normal even in the presence of significant disease. Not reliable for diagnosing or staging fatty liver alone.
• FIB-4 score — a simple calculation using age, ALT, AST, and platelet count. Used as a first-line screening tool for fibrosis risk in primary care. Available free online. NICE recommends FIB-4 as the initial assessment for NAFLD.

What MRI Cannot Show

• Inflammation directly — MRI cannot reliably distinguish simple steatosis from steatohepatitis (NASH/MASH). Liver biopsy remains the only way to definitively diagnose inflammation, though blood biomarkers (e.g. enhanced liver fibrosis [ELF] test) are increasingly used.
• Cause of fatty liver — MRI shows the fat but cannot tell you why it is there. Clinical context (alcohol history, metabolic risk factors, medications) is needed.
• Very early fibrosis — standard MRI sequences are not sensitive to early fibrosis (F1). MR elastography is much better but not available everywhere.

What to Expect During the Scan

A liver MRI takes 25-40 minutes. You lie on your back with a coil placed over your abdomen. You will be asked to hold your breath briefly (10-20 seconds) during some sequences to reduce movement from breathing — this is essential for liver imaging.

If contrast is used, a cannula will be placed in your arm. Liver-specific contrast agents (gadoxetate/Primovist) are sometimes used for detailed assessment, particularly if focal liver lesions need characterisation.

Preparation

You may be asked to fast for 4-6 hours before the scan, particularly if contrast is being used. You may need a recent kidney function blood test (eGFR) for contrast scans.

Treatment Pathways

• Simple fatty liver — lifestyle modification is the primary treatment. Weight loss of 5-7% of body weight can reduce liver fat by 50% or more. Diet (Mediterranean diet, reduced sugar and refined carbohydrates), exercise (150 minutes per week of moderate activity), and alcohol reduction. No medications are currently approved specifically for simple fatty liver in the UK.
• Steatohepatitis (NASH/MASH) — more intensive lifestyle modification. Weight loss of 7-10% needed to improve inflammation. Vitamin E (800 IU/day) is sometimes used off-label for non-diabetic patients. Pioglitazone (a diabetes medication) has evidence for improving NASH. Resmetirom (Rezdiffra) was approved by the FDA in 2024 for NASH with fibrosis — UK availability is pending.
• Fibrosis (F2-F3) — aggressive lifestyle modification plus monitoring. Consider referral to a hepatologist. Regular ultrasound surveillance for liver cancer if cirrhosis is approaching.
• Cirrhosis (F4) — ongoing hepatology care, 6-monthly ultrasound and AFP (alpha-fetoprotein) blood test for hepatocellular carcinoma screening, endoscopy for varices, and management of complications. Liver transplant for decompensated cirrhosis.

UK Statistics

• NAFLD/MASLD affects approximately 1 in 3 UK adults
• Around 20-30% of people with simple fatty liver develop NASH/MASH
• Fatty liver disease is now the leading indication for liver transplant in many Western countries
• Liver disease is the third most common cause of premature death in the UK
• Up to 70% of people with type 2 diabetes have fatty liver
• Most people with fatty liver are undiagnosed — they have no symptoms until advanced disease

Frequently Asked Questions

Related Blood Tests

Blood tests complement MRI for fatty liver assessment:

• Liver function tests (ALT, AST, GGT, ALP) — can indicate inflammation but may be normal in fatty liver.
• HbA1c and fasting glucose — to check for diabetes, a major risk factor.
• Lipid profile — high triglycerides and low HDL are associated with fatty liver.
• Thyroid function — hypothyroidism is a treatable cause of fatty liver.
• FIB-4 score — uses age, ALT, AST, and platelets to estimate fibrosis risk.

Browse Lola Health blood tests

Related Articles

• Can an MRI Detect Cancer?
• MRI Scan for Kidney Problems
• Crohn's Disease MRI